Synthetic biology can serve as a powerful tool for rational drug design. Examples of products that are either FDA approved and/or in development include oncolytic viruses that selectively infect and lyse malignant cells, and the use of viral vectors to deliver gene therapy for the treatment of congenital or degenerative diseases. In addition, bacteriophages are a re-emerging technology that have been FDA-cleared for use as food additives to prevent food-borne bacterial diseases and as diagnostic reagents, and are being investigated in clinical trials as therapeutic agents. Can bacteriophages be optimized to target specific receptors and to obviate host immune response to the specific phage? Are there processes and platforms that can be shared by all three fields to provide synergies in design, development, and production?
Ability Level: Advanced
Session ID: 20924